Core Viewpoint - Scorpio Tankers Inc. provided an update on its average daily Time Charter Equivalent (TCE) rates for the first and second quarters of 2026, along with details on its liquidity and outstanding debt [1][5]. TCE Rate Update First Quarter of 2026 - Average daily TCE revenue for LR2 tankers was $51,000 with 2,095 expected revenue days, and 97% of days contracted [2] - Average daily TCE revenue for MR tankers was $32,000 with 3,300 expected revenue days, and 97% of days contracted [2] - Average daily TCE revenue for Handymax tankers was $34,000 with 1,160 expected revenue days, and 95% of days contracted [2] Second Quarter of 2026 - Average daily TCE revenue for LR2 tankers is expected to be $101,000 with 1,780 expected revenue days, and 16% of days contracted [3] - Average daily TCE revenue for MR tankers is expected to be $36,500 with 3,273 expected revenue days, and 16% of days contracted [3] - Average daily TCE revenue for Handymax tankers is expected to be $32,000 with 1,170 expected revenue days, and 10% of days contracted [3] Liquidity and Debt Update - As of March 20, 2026, total outstanding debt was $589.056 million, down from $628.433 million as of December 31, 2025 [7] - Cash increased from $751.955 million to $974 million during the same period, resulting in net cash rising from $123.522 million to $384.944 million [7] - Availability under revolving credit facilities decreased from $783.876 million to $747.481 million [7] Company Overview - Scorpio Tankers Inc. operates a fleet of 89 product tankers, including 33 LR2, 42 MR, and 14 Handymax tankers, with an average age of 10.1 years [8] - The company has agreements to sell one LR2 and two MR product tankers, expected to close in the second quarter of 2026 [8] - Scorpio Tankers has also secured agreements for four MR newbuildings and four LR2 newbuildings, with deliveries expected between 2026 and 2029 [8]

Core Insights - Hallador Energy Company has signed a three-year agreement to sell nearly all of its remaining accredited capacity to a utility customer at record pricing, expected to generate approximately $86 million in cumulative revenue over the term [1][2] Group 1: Capacity Agreement - The capacity is priced at approximately 2x the current levels in the Company's forward sales book, indicating a significant increase in pricing [1][2] - This transaction is expected to establish a new benchmark for higher capacity pricing at the Merom facility, reflecting strong market demand [2] Group 2: Future Revenue Potential - Assuming the increased pricing levels, capacity revenues could potentially exceed $130 million annually starting in 2029, in addition to energy revenue [2] - The largely fixed cost structure of the Merom power plant suggests that most of the incremental capacity revenue will translate directly to operating cash flow [2] Group 3: Company Overview - Hallador Energy Company is a vertically-integrated Independent Power Producer based in Terre Haute, Indiana, with two core businesses: Hallador Power Company, LLC, and Sunrise Coal, LLC [3]

Core Viewpoint - Vicarious Surgical Inc. has received approval to upgrade its Class A common stock to the OTCQB Venture Market, marking a significant step in its capital markets strategy aimed at a potential Nasdaq listing [1][2][3] Group 1: Company Overview - Vicarious Surgical is a next-generation surgical robotics company founded in 2014, focused on developing technology to enhance surgical efficiency, improve patient outcomes, and reduce healthcare costs [4] - The company utilizes proprietary human-like surgical robots to perform minimally invasive surgeries, aiming to transform the surgical landscape [4] - Vicarious Surgical is backed by notable investors, including Bill Gates and Khosla Ventures, and is headquartered in Waltham, Massachusetts [4] Group 2: Market Strategy - The upgrade to the OTCQB is expected to enhance market visibility and facilitate increased participation from market makers, which may improve trading liquidity [2] - The company believes that trading on the OTCQB is a foundational step towards its goal of relisting on a national exchange, specifically the Nasdaq [3] - The CEO of Vicarious Surgical expressed that this milestone enhances accessibility and liquidity for shareholders and positions the company to engage with a broader investor base over time [3]

Core Viewpoint - Omega Flex, Inc. has declared a regular quarterly dividend of $0.34 per share, payable on April 21, 2026, to shareholders of record on April 9, 2026 [1] Dividend Declaration - The Board of Directors has set the quarterly dividend at $0.34 per share [1] - The dividend will be paid on April 21, 2026, to shareholders who are on record as of April 9, 2026 [1] - Future dividends will be determined based on the company's cash needs, operational results, financial condition, capital expenditure plans, potential acquisitions, and other relevant factors [1]

Core Insights - Emergent BioSolutions Inc. has secured a contract worth approximately $54 million USD to deliver CNJ-016 (Vaccinia Immune Globulin Intravenous) for smallpox preparedness to the U.S. Department of Health and Human Services [1] - The company has also received new orders valued at $6.6 million USD for ACAM2000 (Smallpox Vaccine) from an international government partner, highlighting the global emphasis on biodefense [2] - Emergent's recent agreements with the Government of Canada are valued up to $140 million CAD, reinforcing its role in supporting national security and public health preparedness [3] Contract and Orders - The contract with ASPR is an extension of an existing 10-year agreement, indicating a long-term commitment to smallpox preparedness [1] - The incremental orders for ACAM2000 are part of a recurring relationship with an international customer, emphasizing the importance of global threat preparedness [2] - The multi-year agreements with Canada include over $35 million CAD in orders expected in 2026, showcasing the company's expanding role in international biodefense [3] Product Information - CNJ-016 is indicated for treating complications from vaccinia vaccination, including severe generalized vaccinia and eczema vaccinatum [4] - ACAM2000 is indicated for active immunization against smallpox and mpox in high-risk individuals [10] - Both products have specific safety information and contraindications that are critical for healthcare providers [5][6][12]

Core Insights - Lifeward Ltd. has successfully closed a strategic partnership agreement with Oramed Pharmaceuticals, enhancing its position as a diversified biomedical innovation company with a clear path to profitability [1][2] Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1][3] - The company designs, develops, and commercializes solutions that provide functional and health benefits in both clinical and home settings [3] - Lifeward's product portfolio includes notable innovations such as the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit [3] Strategic Partnership Details - The partnership with Oramed Pharmaceuticals includes the acquisition of Oramed's clinical-stage Protein Oral Delivery (POD™) technology, which opens up significant opportunities in the biotech market [2] - Lifeward has access to up to $47 million in capital from Oramed and other investors, having accessed $10 million of this capital on March 25, 2026 [2] Operational Changes - Following the partnership, Lifeward has made changes to its board of directors, indicating a strategic shift in governance to align with its new objectives [2]

Core Viewpoint - Casella Waste Systems, Inc. will participate in the Gabelli Funds 12th Annual Waste and Sustainability Symposium on April 9, 2026, highlighting its commitment to engaging with investors and stakeholders in the waste management and sustainability sectors [1]. Company Participation - The company’s management will present at the investor conference, indicating an active approach to investor relations and transparency [1]. - Presentation materials will be available prior to the event on the company's investor website, ensuring that investors have access to relevant information [1]. Access to Information - A live webcast link will be posted on the company's investor website, allowing broader access to the presentation for interested parties [1].

Core Insights - Parsons Corporation has been selected as the lead designer for the Virginia Department of Transportation's Interstate 64 Hampton Roads Express Lanes Norfolk Segment 1B project, which aims to enhance the regional transportation network [1][2] Group 1: Project Overview - The total design-build contract value for the HREL Norfolk Segment 1B project is $389 million, which will convert existing lanes into a high-occupancy express shoulder lane and maintain three general-purpose lanes in each direction [2] - The project will create a continuous 45-mile regional Express Lane network, improving travel reliability and reducing congestion in the Hampton Roads area [2] Group 2: Economic and Societal Impact - The project is expected to advance economic and societal improvements in the Tidewater region, reducing congestion and enhancing community mobility [3] - Parsons has a strong track record in delivering complex infrastructure projects, having completed over 10,000 miles of road and highway infrastructure globally [3] Group 3: Company Positioning - This award underscores Parsons' success in securing long-term infrastructure projects, reinforcing its strong presence in the transportation market [3] - Parsons is recognized as a leading provider of complex infrastructure solutions, with capabilities spanning various sectors including national security and global infrastructure [4]

Core Insights - WidePoint Corporation reported significant financial improvements in the second half of 2025, with Adjusted EBITDA and Free Cash Flow increasing over 190% and 325% respectively from the first half to the second half of the year [4]. Financial Highlights - Fourth Quarter 2025 revenues reached $42.3 million, an increase of $4.6 million from the same quarter last year, with a gross margin of 14% [7][9]. - For the full year 2025, revenues totaled $150.5 million, up $8.0 million from 2024, maintaining a gross margin of 14% [10][22]. - The company reported a net loss of $849,000 for Q4 2025, translating to a loss of $(0.09) per share, and a full-year net loss of $2.8 million or $(0.28) per share [7][10]. Operational Highlights - WidePoint secured several contracts, including a $1.3 million managed services contract with a leading beverage bottler and a $1.25 million task order under the Navy Spiral 4 Contract for the U.S. Army [7]. - The company is focused on advancing its margin-accretive contract pipeline, including a SaaS carrier contract with a major U.S. mobile carrier, with revenue recognition expected in the second half of 2026 [6][8]. Strategic Outlook - The company is optimistic about its position for the CWMS 3.0 recompete, despite delays caused by government shutdowns and leadership changes within the DHS [5]. - WidePoint is actively transitioning existing clients to an 'as-a-service' delivery model to enhance revenue visibility and is focused on long-term growth and shareholder value [8].

Core Insights - SeaStar Medical Holding Corporation has expanded its QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base and completed key clinical trial milestones, indicating strong momentum in its business operations [1][2][3] Business Updates - The company has added 13 new customers from top-ranked children's hospitals, increasing its total customer base to 16 [3] - Enrollment in the FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry has been completed with 50 patients enrolled [3] - The pivotal NEUTRALIZE-AKI trial for adult patients with AKI has surpassed the 50% enrollment milestone, with 181 out of 339 patients enrolled [3] - A cardio-renal clinical trial has been initiated to further advance the company's pipeline [1][2] Financial Performance - For the three months ended December 31, 2025, net revenue was approximately $420 thousand, a significant increase from $67 thousand in the same period in 2024, driven by product sales to an expanding customer base [5] - The cost of goods sold for the same period was $12 thousand, resulting in a gross margin greater than 90% [6] - Research and development expenses decreased to $2.2 million from $2.7 million year-over-year, primarily due to reduced consulting and personnel costs [7] - General and administrative expenses also decreased to approximately $1.2 million from $2.1 million, reflecting lower personnel and consulting costs [9] - The net loss for the three months ended December 31, 2025, was approximately $2.9 million, or $0.80 per share, compared to a net loss of approximately $4.4 million, or $8.98 per share, in the same period in 2024 [11] Future Outlook - The company anticipates achieving approximately $2 million in net product revenue in 2026 [8] - Plans to submit a modular Premarket Application (PMA) to expedite the FDA review process for the SCD therapy are underway [8] - The NEUTRALIZE-AKI pivotal trial is expected to complete enrollment by the end of 2026 [8] - The company aims to explore additional regulatory pathways for the SCD therapy to facilitate rapid commercialization [8]